Literature DB >> 8262640

A role for natural antibody in the pathogenesis of leprosy: antibody in nonimmune serum mediates C3 fixation to the Mycobacterium leprae surface and hence phagocytosis by human mononuclear phagocytes.

L S Schlesinger1, M A Horwitz.   

Abstract

We have previously determined that complement receptors on human mononuclear phagocytes and complement component C3 in nonimmune serum mediate phagocytosis of the intracellular bacterial pathogen Mycobacterium leprae, the agent of leprosy. We have also determined that C3 fixes selectively to the major surface glycolipid of M. leprae, phenolic glycolipid 1 (PGL-1). In this study, we have explored the role of natural antibody in nonimmune serum in C3 fixation and C1q binding to M. leprae and PGL-1. At serum concentrations within the range at which phagocytosis of M. leprae is maximal, C3 fixation was mediated by both the classical and the alternative complement pathways. At the low end of this serum concentration range (2.5%), C3 fixation was mediated predominantly by the classical pathway. Consistent with a role for both pathways, C3 fixation to M. leprae was enhanced by the addition of either pure C1q to C1q-depleted serum or pure factor B to factor B-depleted serum. C3 fixation to M. leprae was strictly antibody dependent regardless of the serum concentration used. C3 fixation to M. leprae occurred in nonimmune serum but not in agammaglobulinemic serum unless heat-inactivated nonimmune serum or small amounts of pure immunoglobulin G (IgG) or IgM were added. C3 fixation by both the alternative and the classical complement pathways was mediated by antibody, and the antigen-binding portion of the antibody molecule was required. C3, IgG, IgM, and C1q were readily detected on the surface of M. leprae. Consistent with the previously demonstrated exclusive role of the classical complement pathway in C3 fixation to PGL-1, C1q bound to PGL-1 in a dose-dependent fashion; C1q binding was evident in > 1.25% nonimmune serum. C1q binding to PGL-1 was strictly antibody dependent. When PGL-1 was incubated with pure C1q, little or no C1q bound to PGL-1 unless heat-inactivated nonimmune serum or pure IgG or IgM was added. When PGL-1 was incubated in nonimmune serum, C3 bound directly to PGL-1 and not to anti-PGL-1 antibody, since the amount of C3 bound to PGL-1 was not reduced by acid elution of the antibody. However, the amount of C3 bound to PGL-1 was markedly reduced by hydroxylamine treatment, providing evidence for C3 fixation via a covalent ester bond. Nonimmune serum contained antibody to all four major M. leprae surface carbohydrates. Relative to PGL-1, nonimmune serum contained more antibody to the other surface carbohydrates.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8262640      PMCID: PMC186098          DOI: 10.1128/iai.62.1.280-289.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli.

Authors:  S W Hunter; H Gaylord; P J Brennan
Journal:  J Biol Chem       Date:  1986-09-15       Impact factor: 5.157

2.  Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces.

Authors:  S K Law; N A Lichtenberg; R P Levine
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

3.  Conservation of genomic sequences among isolates of Mycobacterium leprae.

Authors:  J E Clark-Curtiss; G P Walsh
Journal:  J Bacteriol       Date:  1989-09       Impact factor: 3.490

4.  Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation.

Authors:  J A Winkelstein; H S Shin; W B Wood
Journal:  J Immunol       Date:  1972-06       Impact factor: 5.422

Review 5.  Molecular biology and chemistry of the alternative pathway of complement.

Authors:  H J Müller-Eberhard; R D Schreiber
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

6.  Structure and antigenicity of the major specific glycolipid antigen of Mycobacterium leprae.

Authors:  S W Hunter; T Fujiwara; P J Brennan
Journal:  J Biol Chem       Date:  1982-12-25       Impact factor: 5.157

7.  Universal occurrence of antibodies to tubercle bacilli in sera from non-tuberculous and tuberculous individuals.

Authors:  E J Bardana; J K McClatchy; R S Farr; P Minden
Journal:  Clin Exp Immunol       Date:  1973-01       Impact factor: 4.330

8.  Demonstration that the galactosyl and arabinosyl residues in the cell-wall arabinogalactan of Mycobacterium leprae and Mycobacterium tuberculosis are furanoid.

Authors:  M McNeil; S J Wallner; S W Hunter; P J Brennan
Journal:  Carbohydr Res       Date:  1987-09-01       Impact factor: 2.104

9.  Humoral immunity in leprosy: immunoglobulin G and M antibody responses to Mycobacterium leprae in relation to various disease patterns.

Authors:  J Touw; E M Langendijk; G L Stoner; A Belehu
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

10.  Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid.

Authors:  V Mehra; P J Brennan; E Rada; J Convit; B R Bloom
Journal:  Nature       Date:  1984 Mar 8-14       Impact factor: 49.962

View more
  20 in total

1.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

Review 2.  Common themes in microbial pathogenicity revisited.

Authors:  B B Finlay; S Falkow
Journal:  Microbiol Mol Biol Rev       Date:  1997-06       Impact factor: 11.056

3.  Interactions of F1 fractions from different strains of Paracoccidioides brasiliensis with human complement and with human neutrophils.

Authors:  L S Crott; Y M Lucisano-Valim; C L Silva; J E Barbosa
Journal:  Mycopathologia       Date:  1997       Impact factor: 2.574

4.  IgM colocalises with complement and C reactive protein in infarcted human myocardium.

Authors:  P A J Krijnen; C Ciurana; T Cramer; T Hazes; C J L M Meijer; C A Visser; H W M Niessen; C E Hack
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

5.  Opsonization effects on Mycobacterium avium subsp. paratuberculosis--macrophage interactions.

Authors:  J Hostetter; R Kagan; E Steadham
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

6.  Antifungal activity of a human antiglucuronoxylomannan antibody.

Authors:  Z Zhong; L A Pirofski
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

7.  Characterization of the receptor-ligand pathways important for entry and survival of Francisella tularensis in human macrophages.

Authors:  Ashwin Balagopal; Amanda Shearer MacFarlane; Nrusingh Mohapatra; Shilpa Soni; John S Gunn; Larry S Schlesinger
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

8.  Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid.

Authors:  J Scott Ferguson; Jeremy J Weis; Jennifer L Martin; Larry S Schlesinger
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

9.  Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells.

Authors:  M N Saarloos; T F Lint; G T Spear
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

10.  A Mycobacterium leprae gene encoding a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells.

Authors:  J S Schorey; Q Li; D W McCourt; M Bong-Mastek; J E Clark-Curtiss; T L Ratliff; E J Brown
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.